New blood test aims to predict which cancer patients will benefit from immunotherapy
NCT ID NCT07246759
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is developing a blood test called NeutroFlow that measures specific immune cells (neutrophils) to predict whether cancer patients will benefit from immunotherapy. Researchers will collect blood samples from 600 patients with several types of cancer before they start treatment. The goal is to create a tool that helps doctors personalize cancer care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this blood test could help doctors decide which patients are most likely to benefit from immunotherapy, avoiding unnecessary treatments.
- What could go wrong
- This is an early-stage study to develop and validate a test, not a treatment. The test may not accurately predict outcomes for all patients or cancer types.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HNSCC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Heidelberg University Hospital
Heidelberg, 69120, Germany
-
Intituto Europeo di Oncologia SRL
Milan, 20121, Italy
-
Virgen Macarena University Hospital - Servicio Andaluz de Salud
Seville, 41071, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Four-Drug combo erase Triple-Negative breast cancer before surgery?
- Can a Custom-Made vaccine outsmart Triple-Negative breast cancer?
- Can a new PET tracer light up hidden cancers?
- Can a drug combo outsmart a tough breast cancer subtype?
- Can a One-Two punch of radiation and immunotherapy shrink head and neck tumors before surgery?
- Can a new drug combo outsmart triple-negative breast cancer?